SGLT2i use is associated with reduced risks of cardiopulmonary inflammatory complications in cancer patients with diabetes: a retrospective cohort study
In cancer patients with diabetes, pre-treatment SGLT2i use is associated with reduced risks of cardiorespiratory inflammatory complications. Robust prospective studies are warranted to confirm the role of SGLT2i in mitigating multi-system inflammatory risks in this cohort.
Authors
- Yanlin Li (ORCID: https://orcid.org/0000-0003-1614-3228)
- Dan Li (ORCID: https://orcid.org/0000-0002-5586-4055)
- Xin Yu
- Min Jiao (ORCID: https://orcid.org/0000-0001-5496-7995)
- Lingyu Meng (ORCID: https://orcid.org/0000-0002-2328-4849)
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fcvm.2025.1657240
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00